PATENT CLAIM ANALYSIS

Application Number: 15918120
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["514", "04400A"]

Abstract:
This document relates to materials and methods in assessing and treating mammals (e.g., humans) with precursor plasma cell (PC) disorders. Materials and methods for determining if a mammal (e.g., a mammal having a precursor plasma cell disorder) has an elevated level of 2-hydroxyglutarate (2-HG) that can be used to identify the precursor plasma cell disorder as likely to progress to a PC cancer (e.g., multiple myeloma) are provided. Materials and methods for treating a mammal having a precursor PC disorder at high risk of progressing to a PC cancer also are provided.

Claim (Index 5):
The method of  claim 1 , wherein said PC treatment is selected from the group consisting of bortezomib, carfilzomib, ixazomib, thalidomide, lenalidomide, pomalidomide melphalan, vincristine, cyclophosphamide, etoposide, doxorubicin, bendamustine, prednisone, dexamethasone, stem cell transplantation, radiation therapy, daratumumab, elotuzumab, chimeric antigen receptor T cell therapy, and allogeneic stem cell transplantation.

Metadata:
- Claim Count in Document: 38.0
- Percentile: 90.0
- Lexical Diversity: 1.89474
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['11043209', '09821719', '14769888', '14433681', '14438715']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7548872949587537
- 35 USC 102 Novelty (BERT): 0.5026280854343677
- Combined Prediction Score: 0.7296613740063151
- Mean Citation Score: 208.90334
- Max Citation Score: 236.07089
- Similarity Product: 171.06096706562937

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test